PANGENOMIC ANTIVIRAL EFFECT OF REP 2139 IN CRISPR/ Cas9 ENGINEERED CELL LINES EXPRESSING HEPATITIS B VIRUS HBsAg

被引：0
|
作者：
Angelo, Lena [1 ]
Blanchet, Matthieu [1 ,2 ]
Vaillant, Andrew [2 ]
Labonte, Patrick [1 ]
机构：
[1] Inrs Ctr Armand Frappier Sante Biotechnol, Laval, PQ, Canada
[2] Replicor Inc, Montreal, PQ, Canada
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1479C
引用
收藏
页码：S581 / S581
页数：1
相关论文
共 50 条
  • [1] Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigen
    Angelo, Lena
    Vaillant, Andrew
    Blanchet, Matthieu
    Labonte, Patrick
    PLOS ONE, 2023, 18 (11):
  • [2] Targeting Hepatitis B Virus With CRISPR/Cas9
    Seeger, Christoph
    Sohn, Ji A.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2014, 3 : e216
  • [3] Antiviral Activity of CRISPR/Cas9 Ribonucleoprotein Complexes on a Hepatitis B Virus Model In Vivo
    Kostyusheva, A. P.
    Brezgin, S. A.
    Ponomareva, N. I.
    Goptar, I. A.
    Nikiforova, A. V.
    Gegechkori, V. I.
    Poluektova, V. B.
    Turkadze, K. A.
    Sudina, A. E.
    Chulanov, V. P.
    Kostyushev, D. S.
    MOLECULAR BIOLOGY, 2022, 56 (06) : 816 - 822
  • [4] Antiviral Activity of CRISPR/Cas9 Ribonucleoprotein Complexes on a Hepatitis B Virus Model In Vivo
    A. P. Kostyusheva
    S. A. Brezgin
    N. I. Ponomareva
    I. A. Goptar
    A. V. Nikiforova
    V. I. Gegechkori
    V. B. Poluektova
    K. A. Turkadze
    A. E. Sudina
    V. P. Chulanov
    D. S. Kostyushev
    Molecular Biology, 2022, 56 : 816 - 822
  • [5] CRISPR/Cas9 for hepatitis B virus infection treatment
    Cai, Bo
    Chang, Shixue
    Tian, Yuhan
    Zhen, Shuai
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (05)
  • [6] Targeting hepatitis B virus with CRISPR/Cas9 approach
    Martinez, Maria Guadalupe
    Inchauspe, Aurore
    Delberghe, Elodie
    Chapus, Fleur
    Neveu, Gregory
    Alam, Antoine
    Carter, Kara
    Testoni, Barbara
    Zoulim, Fabien
    JOURNAL OF HEPATOLOGY, 2020, 73 : S841 - S842
  • [7] Targeting hepatitis B virus cccDNA using CRISPR/Cas9
    Kennedy, Edward M.
    Kornepati, Anand V. R.
    Cullen, Bryan R.
    ANTIVIRAL RESEARCH, 2015, 123 : 188 - 192
  • [8] Inhibition of Hepatitis B Virus with the Help of CRISPR/Cas9 Technology
    Noor, Sadaf
    Rasul, Akhtar
    Iqbal, Muhammad Shahid
    Ahmed, Bilal
    Akash, Muhammad Sajid Hamid
    Qadir, Muhammad Imran
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2020, 30 (03): : 273 - 278
  • [9] HEPATITIS B VIRUS AND SITE-SPECIFIC NUCLEASES: EFFECTS OF GENETIC MODIFICATIONS IN CRISPR/Cas9 ON ANTIVIRAL ACTIVITY
    Kostyusheva, A. P.
    Brezgin, S. A.
    Zarifyan, D. N.
    Chistyakov, D. S.
    Gegechkory, V., I
    Bayurova, E. O.
    Volchkova, E. V.
    Kostyushev, D. S.
    Chulanov, V. P.
    INFEKTSIYA I IMMUNITET, 2019, 9 (02): : 279 - 287
  • [10] CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
    Ramanan, Vyas
    Shlomai, Amir
    Cox, David B. T.
    Schwartz, Robert E.
    Michailidis, Eleftherios
    Bhatta, Ankit
    Scott, David A.
    Zhang, Feng
    Rice, Charles M.
    Bhatia, Sangeeta N.
    SCIENTIFIC REPORTS, 2015, 5
12345